

17th May, 2025

- | | |
|--|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Dear Sir / Madam,

Subject: Update on USFDA inspection at facility of Sitec in Mahape, Navi Mumbai, India

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 20th February, 2025, regarding the United States Food and Drug Administration (USFDA) current Good Manufacturing Practices ('cGMP') inspection at the analytical testing facility of Sitec Labs Limited, wholly owned subsidiary of the Company ('Sitec') located in Mahape, Navi Mumbai from 18th to 20th February, 2025, we hereby notify that the USFDA, via email communication dated 16th May, 2025 (11.57 pm IST), has classified the above-referred inspection as Voluntary Action Indicated (VAI).

Please take the above information on record.

Thanking you,

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode